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INTRODUCTION 
 
Scabies has been a major health problem in many countries worldwide 
because of its very high prevalence. The estimated prevalence varies from 0.2 
to 71 %.1 Nearly hundred million people are affected worldwide. 
 
It affects people of all races and social classes.2 It spreads rapidly in 
crowded conditions.2 Institutions like nursing homes, prisons and extended care 
facilities are often sites for outbreaks of scabies.  
 
It is a common, intensely pruritic dermatosis, caused by the mite 
Sarcoptes scabiei var hominis. It is highly contagious & transmitted by close, 
skin to skin contact 3.  For atleast 3000 years it has been a very common 
disease. 
 
Scabies remains a major problem in terms of its contagious nature and 
the secondary infections which occur as a result of the disease.In our study, we 
are comparing the use of GBHC, Permethrin and Topical Ivermectin for the 
treatment of scabies. In addition, the epidemiological patterns of the disease 
were ascertained. So, these study findings will play an important role to 
determine the effective drug for patients with scabies. 
 
 
2 
 
REVIEW OF LITERATURE: 
The word scabies is derived from Latin term Scabere which means ‘to 
scratch’4,2. Scabies known by various names like Family itch , 7 year itch, 
camp itch, Norwegian itch, Bonomo’s disease, Acariasis. It is referred to as 
Sarcoptic Mange in animals and Scaly leg in birds4. 
 
HISTORY: 
The history of discovery of the agent causing scabies is fascinating.5 
•
 Aristotle (384-322 BC), was the first to use the term 'akari' to designate 
a wood-dwelling mite.6 
• Giovan Cosimo Bonomo together with Diacinto Cestoni discovered the 
etiologic agent in 18676. They stated that it reproduced through male 
and female union, affirmed it laid eggs6. It was suggested mites could 
get transmitted by clothes and fomites.7 
• Francesco Redi must be honoured as he was Bonomo and Cestoni's 
Master. Although he was not involved directly in discovery, he guided 
them and stimulated their work.8 
• Bonomo was honoured for the discovery and first description of the 
Sarcoptes scabiei by Cumston in the year 1924.9 
• Bonomo's signed letter was noticed by Razzauti in the Library of 
Fraternità di S. Maria of Arezzo Razzauti in the year 1927. 9 
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• Avenzoar first described Scabies mite in 12th century in Spain but did 
not link it with the skin eruption which is associated 10.   
• August Hauptmann was the first person to show the mite in 1654.  
• In a letter to Franseco Redi in 1687, Giovanni Bonomo described and 
drew the mite.11 
• Von Hebra in 1844 stated that scabies was local disease and not internal 
disease.4 
• Mellanby in 1943 described the life cycle of the mite. 4 
Scabies is intensely pruritic and a highly contagious parasitic infestation. 
In the new millennium especially with HIV pandemic it is a re-emerging 
infection and a significant health problem in developing countries.12,13 
 
EPIDEMIOLOGY: 
Nearly hundred million people are affected worldwide. The major 
disease burden is by the developing countries due to poor sanitation and poor 
housing facilities. The disease is more prevalent in the very young, but it is also 
frequent in children and the young adults and thereafter the prevalence declines 
sharply. The disease is more frequent in autumn and winter. This may be 
because of the biological characteristics of the mite. Mites survive for a longer 
duration in the cooler weather. Mites may be sensitive to the human sweat 
which contains antimicrobial peptidethereby leading to reduced prevalence in 
the summer. 
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SCABIES MITE: 
Sarcoptes scabiei var hominis, host specific mite causes human scabies. 
It is an obligate human parasite.   It is a member of the  
                      Class      :  Arachnida 
                      Subclass :  Acari 
                      Order     :  Astigmata 
Family   : Sarcoptidae14,15 
Nearly 15 different varieties or strains have been isolated from various 
hosts, but they are morphologically similar17.Astigmata members are slow-
moving mites. They have thinly sclerotized integuments and spiracles are not 
detectable16,17.  It is a non-haematophagous mite.18 The colour of the mite is 
creamy brown. It has brown sclerotised legs and mouthparts17,19. The adult 
female measures approximately 0.3 to 0.5 mm in length by 0.3 mm width 
whereas the male is slightly smaller measuring around 0.25 mm in length by 
0.2 mm width17.  Larvae are six legged and nymph and adults are eight 
legged17. Suckers are present in first and second legs in adult mites of both 
sexes. It enables them to grip the substrate17. In addition, mites possess spur-
like claws and on their dorsal surfaces, have six to seven pairs of spine like 
projections. 17,19 
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FIGURE 1- Dorsal view of scabies mite 
Difference between male and female mite:17 
 
Death occurs rapidly above temperature of 55 _C. It can survive outside 
the host for 2–3 days.20,24 
The adult mites crawl rapidly on the skin surface, with females 
travelling up to 2.5 cm/min (average speed 1 in/min). 2 
 
ADULT MALE ADULT FEMALE 
Small size compared to female 
0.25mm in length and 0.2 mm in 
width 
Large size compared to male 
0.3-0.5mm in length and 0.3 mm in    
width 
Darker colour compared to female Lighter colour compared to male 
Presence of stalked pulvilli on 4th leg Long setae in 4th leg 
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Life cycle of Sarcoptes scabiei: 
Sarcoptes scabiei undergoes 4 stages in its life cycle; egg, larva, nymph 
and adult.2 
             Upon finding a favourable site, the female mite burrows into skin, and 
in about an hour completely disappears beneath the surface.2 Mite secretes a 
saliva-like substance which dissolves skin and thereby helping in burrowing 
into the skin. Scabies mite burrows at the rate of 0.5-5mm per day15.  Within 
these burrows, male and female mites mate.2 After mating, the impregnated 
female excavates a burrow and lays eggs in it2. The female mite spends the rest 
of her life in the burrow which is commonly 30-60 days whereas the male mite 
dies.  The length of the burrow will be continuously extended by female mite 
and it usually burrows a total length of 1 cm (~½ inch) or more.2 
Developmental stages are 
• Egg 
• Larva 
• Protonymph 
• Tritonymph 
• Adults21 
The female mite begins to lay eggs producing 2 or 3 each day2.  The 
eggs hatch in 3-4 days and within a day of hatching, the larvae begins to crawl 
actively out of the burrow towards the skin surface2. Larvae then excavate 
shallow burrows and feeds in them and molts to nymph after 3 days.  The 
nymphs dig just beneath the surface where it molts to adults within 3-4 days2. 
 The developmental time taken for the eg
days for males and 14 days for females.Male mites live for 1
spend this time searching for female mite and dies after mating 
life time, female mite may lay as many as 180
removed from skin by bathing, scratching, or rubbing of the skin
survive for more than 48
 
FIGURE 2 
 
MODES OF TRANMISSION
The most common method 
contact between the individuals when mites are crawling on the surface of the 
skin2. This contact must be direct skin
transmitted but a quick handshake or hug does not usual
Because infestation often spreads during close physical contact of sexual 
7 
g to develop intoadult takes about 10 
 eggs.  The egg
-72 hours, once they are away from the human body
-LIFE CYCLE OF SCABIES MITE
 :2 
by which scabies is transmitted is by direct 
-to-skin contact for the disease to be 
ly spread scabies. 
-2 days only and 
(22, 23)
. In her 
s are mostly 
2
. Mites do not 
2
. 
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activity, it is sometimes considered as a sexually transmitted disease2. 
However, scabies mite  is often usually passed from person to person in 
situations where people live in close contact, including hospitals, nursing 
homes, hostel, prisons, child care facilities, and institutions.2 
The disease can also be transmitted via prolonged contact with bed linen 
and other clothing from infested hosts.  If relative humidity is more than 30%, 
the mite survives for 2-3 days at room temperature. Inanimate objects that 
might be contaminated with infectious organisms and serve in disease 
transmission are fomites2. Mites may survive for up to 7 days in such inanimate 
objects. Indirect transmission through fomites is not common and usually only 
occurs if these inanimate objects are contaminated by infested hosts 
immediately beforehand2. 
A person is considered to be infectious from the moment of being 
infested until completion of treatment successfully. Linen and clothing are 
considered to be infectious until the completion of treatment or till two weeks 
after the last exposure. After treatment the patient may unknowingly become 
reinfested again through exposure to the primary source of infestation or 
through contact with a different infested source.2 
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FIGURE 3 : MODES OF DISEASE TRANSMISSION 
 
CLINICAL MANIFESTATIONS: 
Scabies has varied clinical manifestations in humans. It mimics many 
other dermatological conditions such as eczema, impetigo, other pyodermas, 
fungal infections and contact dermatitis posing diagnostic difficulty25. The 
clinical signs may differ based upon how advanced the infestation is and the 
sort of inflammation reaction26. Secondary infection usually complicates 
untreated scabies. Pyoderma is a consequence of secondary infection by 
streptococci and Staphylococcus aureus27.  
Classical scabies patients usually have generalized itching which is 
aggravated at night28. For the itching to manifest, it takes nearly 4-6 weeks and 
it is most probably due to sensitization. 
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Classical lesion of scabies: 
Burrows are the classical lesion essential for diagnosing scabies. 
Burrows appear as serpiginous grayish line measuring 5 mm long and it is 
commonly found where stratum corneum is thin and soft and in places where 
there are very less or no hair follicles. 
 
Common sites: 
1) Sides and interdigital web spaces of fingers and toes 
2) Flexor aspect of wrist and elbow 
3) Popliteal fossae 
4) In females- areola 
5) In males- penis, scrotum, gluteal region, umbilicus and belt line29. 
6) In males :  
Inflammatory papules or nodules whichare surmounted by burrows are 
present on male genitalia and are characteristic of Scabies30. Male genitalia 
should be examined thoroughly when a patient is suspected to be suffering 
from scabies30. Genitalia examination helps in clinching the diagnosis. 
This special lesion cannot be visualized with naked eye and hence many 
techniques are available to improve the visualization of mites. 
 
Primary lesions: 
• Papules 
• Pustules 
• Nodules 
• Vesicles 
11 
 
Secondary lesions in scabies: 
 Excoriation 
 Crusting  
Special lesions: 
1. Burrows 
2. Lichen simplex Chronicus 
Other lesions: 
• Bulla 
• Eczematisation 
If the infestation is present for longer duration, the secondary lesions are   
usually more in number and are more obvious than the burrows.The skin rash 
doesn’t usually correlate well with sites of distribution of scabies mite. 
 
Reasons for occurrence of secondary lesions: 
These lesions occur as a result of 
1) Scratching 
2) Secondary infection                  
Carriers in scabies: 
For the infestation with scabies, there is a broad range of responses 
clinically. Yet few individuals remain without manifesting symptoms and signs 
of the disease in spite of infestation by the mite.  This is akin to the response of 
human beings to various other insects such as fleas, and mosquitoes, in which 
also there is a broad spectrum of clinical manifestations. The infested 
individuals who remain without manifesting symptoms and signs of the disease 
despite of infestation are referred to as Carriers. 
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Classification : 
Intense pruritus aggravated at night is one of the main manifestation. 
Skin lesions such as typical comma-like or irregular tunnels which measures 
from a few millimeters up to a few centimeters are seen31. 
Passages are tunneled by a female scabies mite and it positions itself 
toward the end of the tunnel32. Typical serpentine skin lesions or irregular 
tunnels of size ranging from few mm to few cm are of diagnostic value31. 
 
Scabies in young children: 
Vesicles, pustules and nodules are unevenly distributed usually over the 
hands, feet and body folds17. In contrast to adults, head, hands and soles of feet 
may also be involved in addition to other common sites33. 
Scabies burrows, the pathognomonic lesion for scabies occurs often on 
creases of palms. This follows a pattern of scale reminiscent of the ‘wake’ left 
on the surface of water by a moving bird or a ship (Wake sign)34. 
The wake sign is specific for scabies and it can be found out by the 
naked eye and it helps in pointing out the location of the mite and their 
products. 
 
Scabies in elderly: 
The itching may be incorrectly attributed to the condition known as 
senile pruritus thereby hindering the diagnosis and leading to the 
misdiagnosis35. 
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Nodular scabies: 
Cutaneous lesions may present as round, smooth nodules of red/ reddish 
brown colour and measuring approximately 5-8 mm in diameter. These lesions 
are usually present in the areas with very thin skin, like genitals/ inguinal folds. 
 
Vesicular scabies: 
Vesiculobullous scabies is an uncommon variant. It is seen in elderly 
people usually. This entity might mimic Bullous pemphigoid both clinically 
and histologically and even resemble the immunofluorescence findings too.  
The diagnosis is especially difficult when mites/ fecal pellets cannot be 
demonstrated36. The bulla forms as a consequence of mite’s presence in the 
epidermis of host leading to the specific immunological response. There is 
activation of T-Helper-2 cells with increase in the level of Interleukin-5 which 
in turn increases the level of eosinophils and releases proteolyticenzymes near 
basement lamina. This finally results in blister formation37,38.  
 
Homeless people: 
• Pruritus in a homeless shelter should arouse suspicion of diagnosis of 
scabies.  
• Impetigo and eczematisation are common. 
Scabies and HIV: 
Scabies is commonly seen in patients infected with HIV. The more 
severe and unusual forms are commonly seen as the patient becomes immuno 
suppressed. In advanced HIV disease, crusted scabies can occur.39-41 
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Crusted scabies: 
Synonym: Norwegian Scabies 
Danielssena and Boeck described a type of scabies in Lepers in Norway 
and named it as Norwegian scabies42. In these patients huge number of mites 
was present. It has been referred to as ‘Scabies Norvegica Boecki” by Von 
Hebra43.  The term ‘Norwegian’ should be probably discarded and replaced by 
better terms such as Crusted or hyperkeratotic Scabies44,45. It is an uncommon, 
severely disabilitating form and is characterized by infestation of nearly 
millions of mites. Hyperkeratotic skin crust usually develops. 
 
Pathophysiology:46,47 
Generally there are only few mites in classical scabies presumably due 
to scratching which destroys the burrows. This type of scabies occurs in 
individuals with insufficient immune response, thereby allowing the mites to 
multiply. This form is associated with considerably higher morbidity compared 
to classical scabies.  Mentally retarded individuals or persons suffering from 
dementia may succumb to crusted scabies48. Down’s syndrome is often a 
commonassociation.44,49-52 It may be probably because of lack of ability to 
appreciate pruritus.  But the exact reason for association has not been 
completely understood.  
               Crusted scabies might develop in immunocompromised individuals, 
probably due to disease53-55 or treatment including therapy55-58 with 
Infliximab59 and Toclizumab. In the recent past, there are innumerable reports 
of crusted scabies occurring in HIV infected patients and it has been reported in 
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Immune Reconstitution Inflammatory Syndrome60. Use of topical steroids61,62 
and calcineurin inhibitors like pimecrolimus63 may also result in occurrence of 
crusted scabies.  
 
Clinical Features:64,65 
Crusted scabies might be localized, involving only scalp, face, digits or 
soles.Enormous warty crusts may be present on hands and feet, palms and soles 
that might be irregularly fissured and thickened. Initially erythema and scaling 
may start over face, neck, scalp and trunk and later on it may become 
generalised to form erythroderma. Severity of itching may vary. It might be 
absent, mild or sometimes may be intense. Generalised lymphadenopathy can 
be present in few cases.  On investigations, Eosinophil count and Ig E levels 
are elevated. 
It may be misdiagnosed as hyperkeratotic eczema, psoriasis, Darier 
disease, contact dermatitis and Langerhans Cell Histiocytosis.  Diagnosis can 
be confirmed by examination of scraping. It is usually teeming with mites and 
eggs.  
 
 
  
 DIAGNOSIS OF SCABIES:
BASIC DIAGNOSTIC TOOLS:
Ink burrow test: 
Synonym:  Burrow Ink test
The underside of a cartridge pen is rubbed on suspected scabies papule 
and then excess ink is wiped off with an alcohol pad
the tunnel and it is visualized as 
flowing ink) is inexpensive and simple tool. This method is helpful in anxious 
individuals and uncooperative patients. This test gives approximately 30% 
chance of false negative results
 
Tetracycline test: 
An alternative to the burrow ink test is tetracycline test
topical tetracycline is applied and after application and removal of excess 
tetracycline solution with alcohol, examination of the burrow is done with 
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66
. Ink allows tovisualize 
dark irregular track.  Cartridge pen (with free 
67
.  
Diagnosis of scabies
basic diagnostic tests
Ink burrow test
skin scraping test
Adhesive tape test
advanced diagnositic 
tests
Skin biopsy
Dermatoscopy and 
videodermatoscopy
ELISA & PCR
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. Solution of 
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Wood’s light66. Greenish fluorescence is seen due to the remaining tetracycline 
within the burrow. 
 
Skin scraping : 
Gathering specimen for skin scraping is an invasive method. One drop 
of mineral oil is added onto the skin lesion, samples of involved skin are 
gathered using a sterile scalpel. The oil helps in adhering the scraped material 
to the blade. Skin scraping can be suspended in mineral oil and the material 
which is collected is placed on the microscope slide and coverslip is placed 
over it. Scales usually mixes with oil and mites adhere to the oil. Transparent 
nail polish is used to seal the edges to prevent migration of mites beyond the 
coverslip68,69. The collected material is then examined under the microscope to 
identify mites, eggs and fecal pellets.  
Potassium Hydroxide can also be used instead of mineral oil. Potassium 
Hydroxide dissolves keratin and help in improving visibility32. But it can 
dissolve fecal pellets. 
Inability to discover mites is common and does not preclude the 
diagnosis of scabies. The microscopic examination of scrapings collected from 
skin at appropriate sites is usually reckoned as the reference procedure. 
 
Adhesive tape test: 
Adhesive tape is used in this test and it is placed over the skin lesion and 
is then transferred on to the microscopic slide along with tiny separated parts of 
skin. It is presumed that the Sarcoptes mites are present in the epidermis and its 
 upper layers may be released by scratching the skin
include its minimal investment and no requirement for extr
the staff68. The structure of the skin plays a noteworthy part in effective 
collection of mite by this method of using an adhesive tape. 
 
ADVANCED DIAGNOSTIC TOOLS:
Skin biopsy: 
Skin biopsy is an invasive technique for diagnosing 
method makes it conceivable to see the mites and egg in the stratum corneum 
of the epidermis. However, microscopic analysis reveals nonspecific delayed 
hypersensitivity reaction. Mites are often absent. This method has low 
diagnostic sensitivity.Dense infiltrate composedof mononuclear cells with 
numerous eosinophils is present
Onexamination of multiple step sections through the tissue block, pink, pigtail
like structuresthat are connected to the s
can be present in cornified layer
sensitivity73. 
FIGURE 4 &5 : HISTOPATHOLOGY OF SCABIES
4- PIG TAIL APPEARANCE
5- BROWN NUGGETS IN CORNIFIED LAYER
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Dermatoscopy and videodermatoscopy: 
Both dermatoscopy and videodermatoscopy are non-invasive methods. 
With the help of dermatoscope, the skin is observed closely in vivo at a 
magnification power of 10 times. Videodermatoscope gives even more higher 
magnification power of 10-1000 times. Both these techniques can be used to 
screen many sites in a short duration of time. Videodermatoscopy aids in 
precisely identifying the transparent body of mite and the higher magnification 
power helps in visualizing other essential diagnostic components such as eggs, 
scybala74.  This technique is sensitive, effective and yields quicker results 
especially in patients with non-specific symptoms. The higher magnification 
helps in visualizing important diagnostic element and hence the risk of false 
positive results which may be obtained at lesser magnification power can be 
obviated75,76. The mites which are present at the end of the burrow show a 
characteristic Jet plane trail appearance of a burrow or Hang glider appearance. 
These non-invasive techniques are utilized in specialized health care centres as 
these methods are expensive and hence not widely employed in diagnosing 
scabies.  
 
ELISA: 
The sensitivity and specificity of ELISA may vary. The preparation of 
extracts of whole mite is conscientious because the mites which are to be 
cultivated for assays should be taken from the appropriate hosts. The extract 
which is prepared is used in these tests to detect mites. Another impediment to 
use ELISA for detection of scabies mite is that no in vitro culture system exists 
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for this organism77. There is a possibility of cross reactivity between house dust 
mites and Sarcoptes scabiei when extracts from whole mite are utilized for 
serodiagnosis in humans78. 
 
PCR : 
Polymerase Chain Reaction technique helps in detecting mites in the 
suspected samples. In patients presenting with atypical scabies, PCR is 
considered to be trenchant diagnostic method79. Following are the 
disadvantages of ELISA method: 
1) Sensitivity of this test is low 
2) Expensive 
3)  Requirement for specialistic laboratory equipment 
 Due to the above mentioned disadvantages, PCR is considered 
impractical on a larger scale. 
 
DIFFERENTIAL DIAGNOSIS: 
Close mimics: 
 Atopic dermatitis 
 Dyshidrotic eczema 
 Pyoderma 
 Contact dermatitis 
 Insect bite reaction 
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Other differential diagnosis: 
 Dermatitis herpetiformis 
 Psoriasis 
 Bullous pemphigoid 
 Drug eruption 
 Systemic causes of pruritus 
 Delusions of parasitosis 
COMPLICATIONS: 
 Secondary impetiginisation 
 Eczematisation 
 
 Psychological: 
 Discomfort from pruritus can result in insomnia 
 Extensive psychological reverberation due to embarrassment resulting 
from conceptualization of disease which is ignominious or which affects 
underprivileged social classes and 
 Stress associated with necessity to inform contacts (family members, 
sexual partners, inmates and children) as they should also be treated so 
as to assure a cure17. 
 
 Work related considerations17: 
 Absenteeism due to treatment and  
 Occupational endangerment to health care personnel and prison 
employees 
  Keratotic or crusted scabies is highly infectious
 Toxicity associated with local and systemic treatment
 
TREATMENT : 
Scabies requires triple treatment which includes
1) Treatment of the affected patient.
2) Patient’s habiliment and bed linens.
3) Close contact of affected individuals. 
 
Principles of treatment of scabies:
 Proper diagnosis to be established.
 An appropriate medication is to be chosen
 The entire body starting from neck till toes should be treated in adults. 
In babies, the whole body
 All the close contacts should be treated.
TOPICAL
22 
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 including head and face must be treated.
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 Secondary infection,if present, should be treated. 
 Over treatment should be avoided. 
 Follow up is required at first week and at fourth weeks 
 After completion of treatment, clothing and bedding should be washed. 
General advice: 
 All the household members and sexual contacts must be treated at the 
same time as patients even if they don’t have manifestations of the 
disease 
 Patient is advised to take bath and to thoroughly dry afterwards before 
applying medicines. 
 The topical drugs must be gently rubbed into the skin. It should be 
applied all over the body from chin downwards, irrespective of its 
involvement. 
 The topical medicines should be applied to clean, dry skin by the 
patients80. 
 Treatment would be more effective if done in the night before retiring to 
sleep. 
 Contact with oral cavity or eyes must be avoided. 
 Underclothing and sheets must be changed the next day and it must be 
washed properly. 
 Nails to be clipped. 
 Itching may persist for few days but doesn’t require treatment again. 
  
 Topical therapy: 
 Permethrin 5% cream
 Lindane (1% Gamma Benzene Hexa Chloride ) lotion or cream
 Ivermectin 0.5 % cream
 Benzyl benzoate 10% and 25%
 Malathion 0.5% lotion
 Crotamiton 10% cream
 Monosulfiram 25% lotion
 Esdepallethrine 0.63% aerosol
 Precipitated Sulphur 2
Oral Drug :Ivermectin
LINDANE: (ORGANOCHLORINE)
Lindane is a Gamma HexaChloroCyclohexane isomer of Cyclohexane family
Figure 
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6 : Chemical structure of GBHC 
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Mechanism of Action: 
            GBHC inhibits neurotransmission, induces respiratory paralysis and 
muscular paralysis in arthropods and thereby causes death of the mite. 
 
Available Topical Formulations: 
       1% GBHC lotion 
 
Method of Application: 
• Eight to twelve hours overnight application over cool dry skin after 
shower. The patient is instructed to take bath after 12 hours of 
application. 
• Similar application should be repeated after 10 days-14 days. 
• The in vitro efficacy of this drug appears to be equivalent to Benzyl 
Benzoate with death of the mite occurring after 3 hours of exposure. But 
it appears to be less effective than Benzyl Benzoate in vivo. 
• Few cases of failure has been reported due to mites resistant to Gamma 
Benzene Hexa Chloride.  
 
Metabolism : 
 The drug is distributed throughout the body widely. 
 It is metabolized slowly. 
 It is stored in the fatty tissues and also in the brain. 
 Furthermore, traces of Lindane may be detected in the body even after 
many months of application. 
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Pregnancy Category : 
               This compound belongs to the pregnancy category C 
Side Effects: 
 Proper application of the drug, rarely causes toxicity from Lindane. 
 Nevertheless, recurrent exposure or ingestion affects the central nervous 
system adversely. 
 There are many reports of seizures because of this drug81-83.  
 Innumerous systemic toxic effects have been reported which includes 
many cases of aplastic anemia and leukemia84. 
Safety: 
Higher levels of drug are reported in  
 Infants and children 
 Those with reduced fat levels like premature infants85. 
SYNTHETIC PYRETHRINS: 
Permethrin 
Esdepellathrin 
PERMETHRIN: 
Chemical structure: 
 
 
 
 
Figure 7  : Chemical Structure of Permethrin 
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Pyrethrins are originally obtained from species of flowers belonging to 
the genus Compositae. This is related to Chrysanthemum. Due to the instability 
of these compounds chemically and comparative ineffectualness, chemists 
shortly formulated Synthetic pyrethroids like Permethrin. They have broad 
range of activity against lice, ticks, scabies and numerous other Arthropods.  
Permethin is one of the synthetic chemicals belonging to Synthetic 
pyrethroids. 2 parts of 3-phenoxy benzy (6) and 3 parts of cis and trans-3-(2-2-
dichlorovinyl)2,2-dimethylcyclopropanecarboxylate is mixed approximately 
and it is utilized as Permethrin.  
 
Mechanism of action: 
The drug disenables the transport of Sodium across the cell membrane 
of arthropods.  This sodium transport mechanism functions for maintaining 
polarisation of neuromembranes of arthropods86. As a result of the inhibition of 
Sodium transport across neurons, repolarization is delayed and thereby 
paralysis of arthropods occur resulting in death of the organism. 
 
Topical formulations available: 
 Permethrin 5% cream :                                                                                     
Useful for total body topical therapy for scabies 
 Permethrin 1% cream rinse :Used for treating head lice. 
Method of application : 
 Overnight application all over the body starting from the neck except for 
face for duration of eight hours.  
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 Special attention has to be paid for hands and fingernails as these sites 
harbor the largest concentration of mites.   
 Intertriginous sites (including interdigital spaces) require cautious 
application 
 Similar application is recommended to be repeated after a period of one 
week.   
 Single application of permethrin cream left overnight is necessary to 
treat all the close contacts of the patient. 
By and large, it is consented that patient infested with scabies mite must 
be treated with two applications which should be left overnight and to be 
repeated one week later although a study has shown a cure rate of 97.8% with 
single application. 
 
Pharmacokinetics: 
Percutaneous absorption: 
Permethrin is absorbed minimally via percutaneous routs. As a result 
mean systemic absorption after applying Permethrin 5% cream is 
approximately less than 1-2% 
 
Metabolism:       
The drug is metabolized through cleavage of ester and almost the entire 
absorbed compound is excreted via urine approximately within one week.  
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Side effects: 
 Pruritus 
 Mild and transient skin irritation 
 Burning sensation 
 Rarely hypersensitivity reactions can occur where in the drug 
usage has to be discontinued.  
Pregnancy category:   
It belongs to the category B.        
 
Safety: 
Due to the minimum systemic absorption, it is safe to be used topically 
in adults and in infants more than two months of age. 
 
IVERMECTIN: 
Ivermectin was first identified in 1970s. It is an important antiparasitic 
medication. Ivermectin chemically is 22,23-dihydroavermcectin.  
 
FIGURE 8 : STRUCTURE OF  IVERMECTIN 
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Structurally it is a semisynthetic macrocylic lactone and this chemical is 
naturally produced by fermentation action of Streptomyces avermitilis in soil87. 
This compound was identified from samples of soil obtained from Japanese 
Golf course.  Initially it was considered only in veterinary treatment, 
Intensified exploration has lead to the appreciation of its potential use in 
humans.  Extensive research has lead to the approval of drug in 1987 by French 
Regulatory authorities88. 
The drug is lipophilic in nature. It has broad spectrum of activity and has 
miticidal and acaricidal activity89. The drug has potent antihelmenthic activity 
and is used for the same property for veterinary and human medicine. It is 
considered drug of choice for treatment of human onchocerciasis90. It is also 
effectual against lymphatic filariasis91. It is also known to have a high degree of 
toxicity to human ectoparasites including scabies mite. 
 
Mechanism of action: 
The drug exerts its action by disrupting neurotransmission in 
invertebrates which is mediated by Gamma Amino Butyric Acid (GABA) in 
the peripheral Muscles. The mechanism of action provides this drug a safety 
profile due to the significant difference between inverterbrates and mammals as 
far as the distribution of GABA mediated neurons are considered. Gamma 
Amino Butyric Acid (GABA) mediated neurons are present only in Central 
Nervous System in mammals but such neurons are present is peripheral muscle 
in invertebrates.  This property accounts for wider safety margin of this drug in 
mammals as it does not cross the blood brain barrier92,18.       
  
 
 
From the year 1980, Ivermectin is employed effectively and safely via 
subcutaneous route against scabies mite in pigs
and other household pets
effectuality of oral ivermectin for treatment of endoparasites and ectoparasites 
has been proven93.  It has been shown to be effective in scabies, for myiasis in 
children, onchocerciasis, 
considered the drug of choice for treating and to control human 
onchocerciasis93. 
After clinical trials which have been done extensively, ivermectin was 
registered in the year 1986 for its use in humans. Due to its effectuality and its 
Binds to glutamate gated chloride channels present in 
Nerve and muscle cells of inverterbrate parasite
Increases cellular permeability
Hyperpolarisation of Nerve and muscle in 
parasite
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, farm foxes, calves, horse dogs  
93
.  In studies which were done previously, the 
larva currens and pediculosis in humans
92, 18
Paralysis and death of the parasite 
 
. It is now 
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safety concern, community based treatment of onchocerciasis and ivermectin 
has been considered as the strategy of choice.  
 
Adverse effects: 
 Fever 
 Headache 
 Pruritus  
 Myalgia 
 Edema 
 Arthralgia 
The above said adverse effects are seen in 64% of the patients with first 
dose whereas it is seen in 50 % of the patients with second dose93.  
These adverse effects are of lesser or moderate intensity and can be 
treated easily with aspirin and / or antihistamines. It is well tolerated in children 
more than 5 years of age93.  
Meinking et al94  have shown that ivermectin at a single oral dosage of 
150-200 micrograms per kilogram is an efficient treatment for scabies in 
otherwise healthy individuals and also in Human Immunodeficiency Virus 
affected patients.  
Corbett et al found that the drug was effective even in treatment of 
crusted scabies by eradicating a nosocomial outbreak in inpatient HIV 
institution with combination of topical treatment and oral Ivermectin. 
It is highly effective antiparasitic animal drug utilized in various forms 
as injectables, oral and topical formulations. Residues of the drug might reach 
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the environment through animal waste and manufacturing waste and might 
potentially have effects on both terrestrial and aquatic organisms93. Studies 
have shown that ivermectin binds avidly to soil and is subjected to 
photodegradation and biotransformation to lesser active compounds93.Whereas 
it has high toxicity to few aquatic organisms but it is not expected to enter 
aquatic environment93. Comparatively lesser toxicity has been demonstrated as 
regards to bacteria, fungi, earthworms, plants and birds. It has been widely used 
for treatment of sea lice infestations of farmed Scottish Salmon93. 
 
BENZYL BENZOATE: 
Chemical structure:
 
It is an ester of benzoic acid and benzyl alcohol96. 
Source:  derived from Balsam of Peru and tolu96 
 
Mechanism of action: 
              This medication is toxic to the nervous system of the parasite and is 
also effective against ova.  
 
 
34 
 
Formulations available: 
 25% emulsion17 
 It is diluted to a concentration of 25% and it is very efficacious in vitro, 
resulting in death of mites within 3 hours17. 
 It can be used alone (10% or 25% lotion) or together with Sulfiram. 
 In Young children : dosage should be reduced to 12.5% 
Different regimens for application: 
 The medicine should be applied for 3 times within 24 hours without 
intervening bath. 
 Twice application 24 hours apart. 
 Twice application one week apart. 
Toxicity : 
Cutaneous side effects: 
 Skin irritation – Irritant dermatitis over face and scrotum. If used 
repeatedly can cause allergic dermatitis. 
 Xerosis 
 Burning sensation 
 Eczema 
Systemic Side effects:  
          Systemic side effects can occur if  
 Applied on broken skin 
 Children less than 2 years of age have ingested accidentally. 
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Sulfiram component might have the same antabuse effect as Disulfiram, so 
alcoholic abstinence should be advised for a minimum duration of 48 hours96. 
 
Avoid in  
• Pregnancy 
• Lactation 
• Infants 
• Young children < 2 years 
Benzyl benzoate if applied properly, has good effect but if not applied in 
a proper manner, it may result in treatment failure. 
 
SULFUR: 
It is an oldest scabicidal agent96,97. It was not approved by FDA for 
scabies treatment.  
 
Mechanism of action: 
• Antiseptic 
• Antiparasitic 
• Anti seborrhoeic 
• Keratolytic action  
Available formulations: 
• Used as 6% precipitated sulphur for scabies treatment 
• Available as 2-10% creams or ointment 
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Advantages: 
 Topical sulphur can be used safely in  
• pregnancy and  
• neonates, infants less than 2 months of age. 
 Inexpensive 
 Mass treatment in resource poor countries. 
 Can be used when patient cannot tolerate permethrin, lindane and 
ivermectin. 
Side effects: 
• Messy 
• Malodorous 
• Stain clothes and  
• Stings the skin. 
Contraindication:   
Hypersensitivity 
Cautions: 
• Avoid contact with eye and mucous membrane 
• Discontinue if repeated applications are needed for effectiveness and 
hence decreased compliance. 
  
 CROTAMITON: 
Chemical structure:
Crotonyl-N-ethyl-o-toluidine
Available formulations:
10% cream or lotion
Unknown mechanism of action
 
Method of application:
Twice daily application for 5 consecutive days after bathing.
Success rate: varies ranging from 50
 
MONOSULFIRAM:
Chemical name: 
Tetraethyl thiurammonosulfide
Monosulfiram was first used in 1942 to treat scabies in human by 
Percival  
 
Method of application:
After bathing, Monosulfiram emulsi
must be rubbed well once a day for two to three consecutive days.
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Caution: 
As this drug is chemically related to antabuse, alcoholic beverages must 
be avoided during or soon after treatment80. 
In the past, soaps have been used as a preventive measure in infected 
communities80. 
 
MALATHION: 
It is an organophosphorous insecticide 
Its mechanism of action is through irreversible inhibition of 
Acetylcholinesterase enzyme. 
Not recommended nowadays because of its serious adverse effects.  
 
IVERMECTIN: 
Oral Ivermectin is given at a dosage of 200 microgram per kilogram. 
Two doses are given at an interval of 2 weeks. 
 
Special situations: 
Neonates and pregnant women should be treated for scabies only if 
benefit outweighs the risk and if diagnosis is confirmed. 
 
TREATMENT FAILURE 
1) Improper application 
2) Inadequate application 
3) Reinfestation 
4) Resistance 
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NEWER DRUGS: 
The search for finding out ideal scabicide is still in process. Due to the 
emerging resistance to the current drugs, the role of newer drugs in treating 
scabies becomes more important. 
Essential oil of the tea tree: 
 It is an Australian traditional medicine which is used for treating bruises, 
skin infections and insect bites. 
 It is a membrane- active biocide which is extracted from the tree 
Melaleuca alternifolia. 
 Oxygenated terpenoids are the primary active components. 
OTHER NATURAL AGENTS: 
• 20% lippia oil 
• Camphor oil 
• Neem and turmetic paste 
• Coconut and jojoba oil mixture 
PREVENTION OF SCABIES: 
 All the household members and sexual contacts should be treated at the 
same time even if they are asymptomatic. 
 Proper advice to the patient and household members. 
 Persons in close contact with crusted scabies patient must be treated as it 
is very easily transmissible. 
 Early detection of scabies is essential to prevent further transmission to 
other individuals and to prevent other complications like secondary 
bacterial infections. 
AIMS AND OBJECTIVES 
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AIM OF THE STUDY 
 
 
1. To compare the efficacy of Topical Ivermectin and other  
scabicidal agents 
 
2. To assess the improvement in severity of pruritus & Severity of 
lesions   with treatment. 
 
  
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
4.1 Type of study       :   Prospective & Comparative study 
4.2 Study approval    :   Prior to commencement of this study - Thesis & 
    Ethical Committee of  Madras Medical College and  
    Rajiv Gandhi Government General Hospital,  
    Chennai had approved the thesis protocol. 
4.3  Place of study     :  Rajiv Gandhi Government General Hospital 
4.4  Period of study   :  Duration starting from October 2015 to  
August 2016 
4.5  Sample size          :  90 cases 
4.6 Selection of patients: 
a) Inclusion criteria-  
1. Patients of above 5 years and below 60 years of age. 
2. Patients of both sexes. 
3. Patients willing for  topical therapy. 
4.Primary case of scabies. 
5.Patients willing for follow-up in the second and sixth week or if any 
b) Exclusion criteria:  
1. Children below 5 years, elderly patients more than 60 years 
2. Pregnant and lactating women. 
3. Patients who were not willing to come for follow-up. 
4. Any serious systemic illness. 
5.Prior use of topical or systemic scabicide in last 4 weeks 
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6.Patients on radiotherapy, steroids or other immunosuppressive drugs for  
   any systemic or cutaneous indication 
7. Hypersensitivity to permethrin or ivermectin. 
4.7 Study procedure: 
 Around 90 patients with Scabies were selected from the patients 
attending out-patient clinic in Department of Dermatology, Madras Medical 
College. All patients were explained about the disease, benefits and possible 
side effects of treatment. Informed written consent was obtained from all 
patients before initiation of treatment. Detailed case history of each patient with 
reference to the duration of itching, worsening during night, similar illness in 
family members or inmates was noted. 
Clinical features like classical site of involvement, morphology of 
lesions, and other associated systemic and cutaneous disorders were noted. 
Thorough clinical examination of classical sites with magnifyinglens, burrow 
ink test or examination after applying mineral oil application was done. 
The diagnosis was made after detailed history and clinical examination 
In doubtful cases, demonstration of scabies mite, eggs or faeces was done by 
scraping from burrows or finger nails. 
The patients were randomly allotted to any one of the following three 
treatment groups after calculating their Severity of Pruritus and Severity of 
lesions. 
Group A comprised patients who will be given 1% GBHC lotion. . 
Group B comprised patients who will be given 5% Permethrin cream 
Group C comprised patients who will be given 0.5% Ivermectin cream. 
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4.8 Follow Up Assesment : 
SCREENING PROCEDURES or VISITS: Patients were advised to 
come for review after 1 week for second application and in third week and in 
sixth week. 
ASSESSMENT OF PARAMETERS98: 
             Parameters used to compare the efficacy of the groups by was based on 
improvement in  
1) severity of pruritus 
2) severity of the disease 
1) Severity of pruritus was evaluated by Visual Analogues Scale (VAS). 
VAS was considered as a 10 cm line, in which point 0 (zero) refers to 
existence of no pruritus and point 10 refers to the most severe pruritus. 
According to this scale, we scored pruritus of the patients 
Point 1 to 3     -   Mild pruritus 
Point 4 to 6     -   Moderate pruritus 
Point 7 to 10   -   Severe pruritus 
2) Severity of the disease is measured according to the number of 
lesions present. It can be graded as 
Mild           -     less than or equal to 10 lesions 
Moderate   -     11-49 lesions 
Severe       -      more than or equal to 50 lesions or  
          Crusted 
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         Severity scores of 1, 2, 3 and 4 were assigned to scabies cases recorded 
as mild, moderate, severe and crusted, respectively. 
Patients were then divided into three categories based on these 
parameters into Good Responders, Moderate Responders &Poor Responders. 
Good Responders : 
Complete resolution of lesions 
Moderate  Responders : 
Patients post treatment,  >50% improvement in pruritus and severity of 
lesions score 
Poor Responders : 
Patients post treatment improvement less than or equal to 50%  
Cases were followed up for a period of two more months to look for 
relapse in the patients. In patients who had relapsed, demonstration of mites 
was done to confirm the diagnosis. 
 
4.9 Variables studied: 
Dependent variable: Severity of pruritus and severity of lesions 
Independent variables: 
i) Age  
ii) Sex 
iii) occupation  
iv) Socio economic status 
v) Symptoms 
vi) Secondary infection 
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vii) Associated skin diseases 
viii) Presence of similar complaints in inmates and family members (Inmates 
are those who are living and sharing bed with the patient – for example 
those living in hostel)  
ix) Dermatological Examination 
x)     Blood Investigations 
Patient were followed up for two more months to look for signs of 
relapse. In cases of relapse, scraping was done to demonstrate mites. 
 
4.10 Ethical consideration 
 All the patients/ legal guardians were given an explanation of the study 
and about the investigative and treatmental procedures with their merits and 
demerits, expected results, and possible complications. If the patient or the 
guardian for children had agreed, then the case had been selected for this study. 
The study did not involve any additional investigation or any significant risk. It 
did not cause economic burden to the patients. The study was approved by the 
institutional review board prior to commencement of data collection. Informed 
consent was taken from each patient/guardian. Data was collected by approved 
data collection form. 
 
4.11 Data collection 
Data were collected by pre-tested structured questionnaire. Data were 
collected from all the respondents by direct interview after getting informed 
written consent from them or from their legal guardian. 
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4.12 Data analysis 
Data analysis was done both manually and by using computer. 
Calculated data were arranged in systemic manner, presented in various table 
and figures and statistical analysis was made to evaluate the objectives of this 
study with the help of Statistical Package for Social Science (SPSS). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATIONS AND RESULTS  
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OBSERVATION AND RESULTS 
 
 
This prospective and comparative study was carried out to determine the 
favourable treatment modality for patients suffering from scabies. Ninety 
patients with Scabies were selected purposively from Department of 
Dermatology of Madras Medical College and Rajiv Gandhi Government 
General Hospital  during the period of 1 October 2015 to 31 August 2016. All 
cases were evaluated clinically and essential investigations necessary for 
diagnosis were carried out. Severity of pruritus and Severity of lesions score of 
patients at baseline were calculated and recorded. Patients were then randomly 
divided into three groups and started on treatment with Topical ivermectin, 
topical permethrin and topical GBHC. Patients response to treatment was 
followed up with Severity of pruritus score and severity of lesions score at 
second, third and sixth week of treatment. Based on the assessment of these 
scores, the response to treatment was categorised into Good, Moderate and 
Poor. All data were collected and analysed and results derived. 
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TABLE 1- DISTRIBUTION OF STUDY POPULATION ACCORDING 
TO AGE AND SEX 
 
         It was observed from our study that nearly 45 out of  patients belonged to 
the younger age group ranging from 6-25. Mean age group of the study 
population is 27.66 years. 
 
CHART 1- DISTRIBUTION OF STUDY POPULATION  
ACCORDING TO AGE 
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Age / Sex Male n (%) Female n (%) Totaln(%) 
6-15 12 (13.3%) 10(11.1%) 22 (24.4%) 
16-25 13(14.4%) 10(11.1%) 23 (25.5%) 
26-35 9(10%) 9(10%) 18 (20%) 
36-45 7(7.77%) 9(7.77%) 16 (17.7%) 
46-55 5(5.55%) 6(6.66%) 11 (12.2%) 
 TABLE 2 : DISTRIBUTION OF STUDY
 
CHART 2 : DISTRIBUTION OF STUDY
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 TABLE 4- DISTRIBUTION OF STUDY POPULATION ACCORDING 
TREATMENT 
GROUP 
A ( GBHC) 
B (PERMETHRIN)
C (IVERMECTIN)
TOTAL 
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TO SEX 
Male 
n(%) 
Female 
n(%) 
16 (17.8%) 14(15.6%) 
 
15(16.7%) 15(16.7%) 
 
16(17.8%) 14(15.6%) 
47 43 
 
 DISTRIBUTION OF STUDY POPULATION 
ACCORDING TO SEX 
A ( GBHC)
B 
(PERMETHRIN) C (IVERMECTIN)
Treatment group
Male Female
Total 
N 
30 
30 
30 
90 
 
 
 TABLE 5- DISTRIBUTION OF STUDY POPULATION ACCORDING 
 
 
 
 
 
 
Scabies was most common in urban population in our study group .  Out 
of the 90 patients studied, nearly 62 (68.9%) patients belonged to urban area 
whereas 28 (30.1%) belonged to 
 
 
Chart -5 : DISTRIBUTION OF SCABIES IN 
RURAL & URBAN POPULATION
TREATMENT 
GROUP
A ( GBHC)
B (PERMETHRIN)
C (IVERMECTIN)
52 
TO URBAN/RURAL RESIDENCE 
rural area. 
URBAN
62
69%
RURAL
28
31%
URBAN RURAL
 
URBAN 
n (%) 
RURAL
n (%)
 20 (22.2%) 10 (11.1%)
 25(27.8%) 5(5.6%)
 17(18.9%) 13(14.4%)
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TABLE 6 : DISTRIBUTION OF STUDY POPULATION IN  
RURAL AREA 
 
 
CHART 6 :DISTRIBUTION OF STUDY POPULATION IN  
RURAL AREA 
 
 
 
MALE
21%
FEMALE
47%
CHILDREN
32%
Age / Sex NO OF PATIENTS n (%) 
MALE 6 
FEMALE 13 
CHILDREN 9 
TOTAL 28 
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TABLE 7 : DISTRIBUTION OF STUDY POPULATION IN  
URBAN AREA 
 
 
CHART 7 : DISTRIBUTION OF STUDY POPULATION IN  
URBAN AREA 
 
 
 
47%
35%
18%
MALE
FEMALE
CHILDREN
Age / Sex NO OF PATIENTS n (%) 
MALE 29 
FEMALE 22 
CHILDREN 11 
TOTAL 62 
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TABLE 8- DISTRIBUTION OF STUDY POPULATION ACCORDING 
TO SOCIOECONOMIC STATUS 
 
 
 
 
 
 
 
               Scabies was most common in lower socioeconomic group according 
to modified kuppusamy scale.  In lower socioeconomic group it is more 
common probably due to overcrowding, poor sanitation and unhygienic 
environment. 
 
CHART  8- DISTRIBUTION OF STUDY POPULATION ACCORDING 
TO SOCIOECONOMIC STATUS 
CLASS 2
1
1%
CLASS 3
18
20%
CLASS 4
40
45%
CLASS 5
31
34%
CLASS 2
CLASS 3
CLASS 4
CLASS 5
SOCIOECONOMIC 
STATUS 
NO OF PATIENTS 
CLASS 2 1(1%) 
CLASS 3 18(20%) 
CLASS 4 40(45%) 
CLASS 5 31 (34%) 
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TABLE 9- DISTRIBUTION OF STUDY POPULATION ACCORDING 
TO WHETHER INMATES- AFFECTED OR NOT 
 
 
 
 
 
In our study group, 69 patients, i.e. 76.7% gave similar history of itching 
and skin lesions in close contacts and family members . 20 children, 21 female 
and 28 male patients had history of scabies in their close contacts. 
 
 
CHART 9- DISTRIBUTION OF STUDY POPULATION ACCORDING 
TO WHETHER INMATES- AFFECTED OR NOT 
 
AFFECTED, 69
NOT 
AFFECTED, 21
AFFECTED
NOT AFFECTED
INMATES NO OF PATIENTS 
AFFECTED 69(76.7%) 
NOT AFFECTED 21(23.3%) 
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TABLE 10- DISTRIBUTION OF STUDY POPULATION ACCORDING 
TO DURATION OF DISEASE 
 
            In our study, majority of patients, nearly 47 patients (52.2%) presented 
with more than 15 days duration of symptoms. 
 
CHART 10- DISTRIBUTION OF STUDY POPULATION ACCORDING 
TO DURATION OF DISEASE 
 
 
(IN DAYS)
0-7
7-14
>15
(IN DAYS)
0-7
Aug-14
>15
DURATION OF SYMPTOMS 
(IN DAYS) 
NO OF PATIENTS 
n (%) 
0-7 6 (6.7%) 
8-14 37 (41.1%) 
>15 47(52.2%) 
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TABLE 11-  DISTRIBUTION OF STUDY POPULATION ACCORDING 
TO BLOOD GROUP 
BLOOD GROUP NO OF PATIENTS n (%) 
A +ve 24 
A –ve 2 
B+ve 25 
B –ve 2 
O+ve 34 
AB +ve 2 
AB -ve 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHART 11-  DISTRIBUTION OF STUDY POPULATION  
ACCORDING TO BLOOD GROUP 
27%
2%
28%2%
38%
2%1%
A +ve
A –ve
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O+ve
AB +ve
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         Scabies was most common among O positive individuals in our study 
group. Nearly 34 (38%) patients out of 90 patients belonged to O positive 
blood group. 
 
TABLE 12 :PREVALENCE OF SECONDARY INFECTION IN STUDY 
POPULATION 
 
 
 
 
 
 
  In the study population, out of 90 patients, nearly 17 patients, that is 
18.8 % of patients had associated secondary infections. 
 
 
CHART 12 : PREVALENCE OF SECONDARY INFECTION IN STUDY 
POPULATION 
PRESENT, 19%
ABSENT, 81%
PRESENT
ABSENT
SECONDARY SKIN 
INFECTION 
NO OF PATIENTS n (%) 
PRESENT 17 (18.8%) 
ABSENT 73(81.11%) 
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TABLE 13 :PREVALENCE OF SECONDARY INFECTION IN STUDY 
POPULATION ACCORDING TO AGE AND SEX 
 
 
 
 
CHART 13 :PREVALENCE OF SECONDARY INFECTION IN STUDY 
POPULATION ACCORDING TO AGE AND SEX 
 
 
29%
47%
24%
MALE FEMALE CHILDREN
Age / Sex NO OF PATIENTS n (%) 
MALE 5 
FEMALE 8 
CHILDREN 4 
TOTAL 17 
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TABLE 14 :PREVALENCE OF ASSOCIATED SKIN DISEASE IN 
STUDY POPULATION 
 
 
          Out of the 90 patients studied, 9 (8.88%) patients had associated 
dermatophyte infection and 17 (18.8%) patients had associated secondary 
infection and others had no associated skin manifestations. 
 
 
 
CHART 14 :PREVALENCE OF ASSOCIATED SKIN DISEASE IN 
STUDY POPULATION 
 
 
DERMATOPHYT
E INFECTION
9%
SECONDARY 
BACTERIAL 
INFECTION
19%
NIL
72%
ASSOCIATED SKIN DISEASES NO OF PATIENTS n (%) 
DERMATOPHYTE INFECTION 9 (8.88%) 
SECONDARY BACTERIAL 
INFECTION 17 (18.8%) 
NIL 66(72.22%) 
 TABLE 15 : PREVALENCE OF ASSOCIATED SKIN DISEASE IN 
STUDY POPULATION ACCORDING TO AGE AND SEX
 
 
 
 
 
 
 
 
CHART 15 : PREVALENCE OF ASSOCIATED SKIN DISEASE IN 
STUDY POPULATION ACCORDING TO 
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AGE AND SEX
MALE
27%
FEMALE
50%
CHILDREN
23%
 NO OF PATIENTS n (%)
 
7 
 
13 
 
6 
 
26 
 
 
 
 
 TABLE16 : PREVALENCE OF HIV INFECTION IN STUDY 
 
 
 
 
 
          Seven patients were found to be HIV positive in our study group. Among 
the HIV positive patients, six were males and one female patient was found to 
be positive. 
 
CHART 16 : PREVALENCE OF HIV INFECTION IN STUDY 
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7 (7.8%) 
 
83(92.2%) 
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COMPARISON OF TREATMENT GROUP: 
 Overall significance of treatment groups was assessed by using  
Friedman test to find out the p value and chi square value.  
 Post hoc analysis was done with Wilcoxon Signed Rank tests to 
determine which group had significant improvement. 
 
AT PRESENTATION: 
There was no statistical significant difference in the severity of pruritus 
and severity of lesion score in all the three groups . 
 
i) SEVERITY SCORE FOR PRURITUS: 
               Using Friedman test, the severity score for pruritus of the three groups 
were compared and the analysis revealed Chi square value of 8.083 at degree of 
freedom of 2 and p value of  .018 which was insignificant. 
Z Drug A Drug B Drug C 
Drug A -NA- -1.225  p(.209) -1.852 p(.064) 
Drug B -1.225  p(.209) -NA- -.729 p(.429) 
Drug C -1.852 p(.064) -.729 p(.429) -NA- 
 
TABLE 17 :  COMPARISON OF PRURITUS SCORE AT BASELINE 
 P value 
GBHC Vs Permethrin p <0.05 
GBHC vs Ivermectin p <0.05 
Permethrin Vs Ivermectin p <0.05 
Chi square value :  8.083    degree of freedom: 2 
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          The above table shows comparison of severity scores using Wilcoxon 
signed rank test and the p values obtained for severity score for pruritus is 
insignificant. 
 
ii) SEVERITY SCORE FOR LESIONS: 
The severity score for lesions of 3 groups at the time of presentation was 
compared using Friedman test and it revealed Chi square value of 2.526  at 
degree of freedom 2 and there was no significant difference in the severity 
scores (0.283). 
Z Drug A Drug B Drug C 
Drug A -NA- -.729 (p:0.466) -2.189 (p:0.029) 
Drug B -.729 (p:0.466) -NA- -0.809 (p:0.418) 
Drug C -2.189 (p:0.029) -0.809 (p:0.418) -NA- 
 
TABLE 18 :  COMPARISON OF LESIONS SCOREAT BASELINE 
 P value 
GBHC VsPermethrin p <0.05 
GBHC vsIvermectin p <0.05 
PermethrinVsIvermectin p <0.05 
Chi square value :  2.526    degree of freedom: 2 
 
         From the above table we can see that p values obtained for severity score 
for lesions in each group were not statistically significant at the time of 
presentation 
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AT THIRD WEEK: 
              At the time of first follow up after completion of two applications of 
scabicidal agents, improvement in terms of severity of pruritus and severity of 
lesions in each group were again reassessed to find out the effects of the drug. 
 
i) SEVERITY SCORE FOR PRURITUS: 
The pruritus severity score of the three groups were compared using 
Friedman test and the analysis revealed Chi square value of 51.185 at degree 
of freedom of 2.p value being less than 0.001 revealed significant difference 
in pruritus severity scores in the three groups. 
Z Drug A Drug B Drug C 
Drug A -NA- -1.808(p: .071) -4.829 (p <0.001) 
Drug B -1.808(p: .071) -NA-          -4.821 (p <0.001) 
Drug C -4.829 (p <0.001) -4.829 (p <0.001) -NA- 
 
TABLE 19 :  COMPARISON OF PRURITUS SCORE AT THIRD WEEK 
 P value 
GBHC VsPermethrin p <0.05 
GBHC vsIvermectin (p <0.001) 
PermethrinVsIvermectin (p <0.001) 
Chi square value :  51.185    degree of freedom: 2 
 
To find out which group had caused significant improvement in severity 
of pruritus - Post hoc analysis with Wilcoxon signed-rank tests was conducted 
with a Bonferroni correction applied, resulting in a significance level set at p < 
0.017. Median (IQR) perceived effect levels for drug A, drug B and drug C   
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trial were 5,4 and 1 respectively. There were no significant differences between 
drug B and Drug A lesions score trials (Z = -1.808, p = 0.071). However, there 
was a statistically significant reduction in pruritus severity in the drug C vs 
drug A trial (Z = -4.829, p = <0.001) and Drug C vs drug B trial (Z= -4.821, p= 
<0.001). 
 
ii)SEVERITY SCORE FOR LESIONS: 
The lesions severity score of the three groups were compared using 
Friedman test .Statistical analysis revealed Chi square value of 43.948 at 
degree of freedom of 2.  p value being less than 0.001 revealed significant 
difference in lesions severity scores in the three groups. 
Z Drug A Drug B Drug C 
Drug A -NA- -1.893 (p: 0.058) -4.790 (p: 
<0.001) 
Drug B -1.893 (p: 0.058) -NA- -4.551 (p: 
<0.001) 
Drug C -4.790 (p: 
<0.001) 
-4.551 (p: 
<0.001) 
-NA- 
 
TABLE 20 :  COMPARISON OF LESIONS SCORE AT THIRD WEEK 
 P value 
GBHC VsPermethrin p <0.05 
GBHC vsIvermectin (p <0.001) 
PermethrinVsIvermectin (p <0.001) 
Chi square value :  43.948    degree of freedom: 2 
 
 
68 
 
To assess which group had caused statistically significant improvement 
in severity of  lesions - Post hoc analysis with Wilcoxon signed-rank tests was 
conducted after applying Bonferroni correction, which resulted in a 
significance level set at p <0.017. Median (IQR) perceived effect levels forthe 
drug A, drug B and drug C   trial were 12.5, 12.00 and 1.5 respectively. Drug B 
and Drug A lesions score trials revealed no significant differences between 
these groups (Z = -1.893, p = 0.058). However, there was a statistically 
significant reduction in  lesions severity in the drug C vs drug A trial (Z = -
4.790, p = <0.001) and Drug C vs drug B trial (Z= -4.551, p= <0.001). 
 
AT SIXTH WEEK FOLLOW UP: 
              At the time of second follow up in the sixth week, amelioration in 
terms of severity of pruritus and severity of lesions in each group were 
reassessed again to find out the effects of the drug.         
 
i) SEVERITY SCORE FOR PRURITUS: 
The pruritus severity score of the three groups were compared using 
Friedman test and the analysis revealed Chi square value of 52.541 at degree 
of freedom of 2.  p value being less than 0.001 revealed significant difference 
in pruritus severity scores in the three groups. 
Z Drug A Drug B Drug C 
Drug A -NA- -4.463 (p<0.001) -4.758 (p<0.001) 
Drug B -4.463 (p<0.001) -NA- -4.667 (p<0.001) 
Drug C -4.758 (p<0.001) -4.667 (p<0.001) -NA- 
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TABLE 21 :  COMPARISON OF PRURITUS SCORE AT SIXTH WEEK 
 P value 
GBHC Vs Permethrin P<0.001 
GBHC vs Ivermectin p <0.001 
Permethrin Vs Ivermectin p <0.001 
Chi square value :  52.541    degree of freedom: 2 
 
             To determine which drug had caused significant improvement in 
severity of pruritus - Post hoc analysis with Wilcoxon signed-rank tests was 
conducted after applying Bonferroni correction, resulting in a significance level 
set at p < 0.017. Median (IQR) perceived effect levels for drug A, drug B and 
drug C   trial were 3,1 and 0 respectively. There were statistical significant 
differences between drug B and Drug A lesions score trials (Z = -4.463, p 
<0.001).  There was a statistically significant reduction in pruritus severity in 
the drug C vs drug A trial (Z = -4.463, p = <0.001) and Drug C vs drug B trial 
(Z= -4.758, p<0.001). 
 
ii) SEVERITY SCORE FOR LESIONS: 
The lesions severity score of the three groups were compared using 
Friedman test .Statistical analysis revealed Chi square value of 46.137 at 
degree of freedom of 2.  p value being less than 0.001 revealed significant 
difference in lesions severity scores in the three groups. 
Z Drug A Drug B Drug C 
Drug A -NA- -4.098(p: <0.001) -4.634(p: <0.001) 
Drug B -4.098 (p: <0.001) -NA- -4.026(p: <0.001) 
Drug C -4.634(p: <0.001) -4.026(p: <0.001) -NA- 
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TABLE 22 :  COMPARISON OF LESIONS SCORE AT SIXTH WEEK 
 P value 
GBHC Vs Permethrin P<0.001 
GBHC vs Ivermectin p <0.001 
Permethrin Vs Ivermectin p <0.001 
Chi square value :  46.137    degree of freedom: 2 
 
         To assess which group had caused statistically significant improvement in 
severity of lesions - Post hoc analysis with Wilcoxon signed-rank tests was 
conducted with Bonferroni correction applied, which resulted in a significance 
level set at p < 0.017. Median (IQR) perceived effect levels forthedrug A, drug 
B and drug C   trial were 6,2 and 0 respectively. Drug B and Drug A lesions 
score trials revealed significant differences between these groups (Z = -4.098, p 
= 0.058). However, there was a statistically significant reduction in  lesions 
severity in the drug C vs drug A trial (Z = -4.634, p = <0.001) and Drug C vs 
drug B trial (Z= -4.026, p= <0.001) 
 
TABLE 23 : COMPARISON OF SEVERITY OF PRURITUS: 
 
AT 
PRESENT
ATION 
SECOND 
WEEK 
FOLLOW 
UP 
THIRD 
WEEK 
FOLLOW 
UP 
SIXTH 
WEEK 
FOLLOW 
UP 
A ( GBHC) 86.7% 66.7% 10% 0% 
B (PERMETHRIN) 90.0% 70% 0% 0% 
C (IVERMECTIN) 86.7% 20.6% 0% 0% 
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             In group A (GBHC), there was 20% reduction in the severity score for 
pruritus at the time of second application. In Group B also there was 20% 
reduction in the severity score for pruritus during second application. Whereas 
in Group C there was 66 .1% reduction in the score at time of second 
application of medication. 
 
TABLE 24 : COMPARISON OF AVERAGE OF PRURITUS IN  
EACH GROUP AT EACH VISIT 
 
AT 
PRESENT
ATION 
SECOND 
WEEK 
FOLLOW 
UP 
THIRD 
WEEK 
FOLLOW UP 
SIXTH 
WEEK 
FOLLOW UP 
A ( GBHC) 10 9 7 5 
B (PERMETHRIN) 10 9 6 2 
C (IVERMECTIN) 10 4 1 0 
 
          This table compares the severity of pruritus in each group at each visit. 
Average of maximum  severity score of pruritus has been taken and tabulated.  
 
 
 
CHART 17 - COMPARISON OF AVERAGE OF PRURITUS IN EACH 
GROUP AT EACH VISIT 
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The mean Severity of pruritus score across all the treatment groups 
when compared showed that, patients treated with Ivermectin had the fastest 
and the maximal response. Both the initial response and the end point was 
better in Ivermectin group patients. Second best response was seen in 
permethrin group.  
 
TABLE 25 : COMPARISON OF AVERAGE OF LESIONS IN EACH 
GROUP AT EACH VISIT: 
 AT 
PRESENT
ATION 
SECOND 
WEEK 
FOLLOW UP 
THIRD WEEK 
FOLLOW UP 
SIXTH WEEK 
FOLLOW UP 
A ( GBHC) 56 45 3 0 
B (PERMETHRIN) 54 35 2 0 
C (IVERMECTIN) 56 25 0 0 
 
This table compares the severity of lesions in each group at each visit. 
Average of maximum severity score of lesions has been taken and tabulated.  
 
CHART 18 :   COMPARISON OF AVERAGE OF LESIONS IN EACH 
GROUP AT EACH VISIT 
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The average of Severity of lesions score across all the treatment groups 
when compared showed that, patients treated with Ivermectin had the fastest 
response. But later on all the drugs had similar response at the sixth week 
follow up. 
 
Table 26 :  RESPONSE TO TREATMENT IN STUDY GROUPS 
TREATMENT 
GROUP 
 
POOR n (%) 
 
MODERATEn(%) 
 
GOODn(%) 
A ( GBHC) 10 (33.3%) 17(56.7%) 3(10.0%) 
B (PERMETHRIN) 0 19(63.3%) 11(36.7%) 
C (IVERMECTIN) 0 4(13.3%) 26(86.6%) 
 
           More than 86 % of patients treated with Ivermectin had good response 
to treatment while only 36.7% % of those treated with permethrin and 3% of 
those treated with GBHC  had good response to treatment. Poor response was 
seen in 33.3 % of GBHC patients compared to the 0% in patients receiving 
Permethrin and Ivermectin.  
 
 
Chart19 :  RESPONSE TO TREATMENT IN STUDY GROUPS 
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SIDE EFFECTS: 
        No side effects was observed in all the study groups 
RELAPSE: 
TABLE 27 : RELAPSE IN TREATMENT GROUP 
 
 
 
 
 TABLE 28 : RELAPSE IN EACH TREATMENT GROUP 
 
 
 
 
 
 
Out of the 90 patients studied, there was a relapse in 7 ( 7.8%) of 
patients. 
Out of the 7 relapsed patients, 5 belonged to Group A (GBHC) and 2 
patients belonged to Group B (Permethrin ). There was no relapse in group C 
(Ivermectin). Treatment group is significantly associated with relapse. In 
Group B and Group A, significant association with relapse and treatment group 
noted with degree of freedom being 2 and at p value of 0.053 
  
RELAPSE IN 
TREATMENT GROUP 
NO  OF PATIENTS 
n(%) 
No relapse 83 
Relapse 7 
RELAPSE IN 
TREATMENT GROUP 
NO  OF PATIENTS 
n(%) 
A(GBHC) 5 (5.6%) 
B(PERMETHRIN) 2 (2.2%) 
C(IVERMECTIN) 0 (0%) 
TOTAL 7 (7.8%) 
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RESPONSE TO THE TREATMENT: 
On using chi square test for assessing the treatment response, It was 
found that 86.6% good response was seen in Ivermectin group compared to 
36.7% response in Permethrin group and 10% in GBHC group at the time of 
second application. This is statistically significant with chi square value of 64 
and at p value of <0.001 and degree of freedom being 2. 
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DISCUSSION 
 
 
This prospective, observational and comparative study was conducted 
among 90 patients with Scabies presenting to the Out patient Department of 
Dermatology, Madras Medical College and Rajiv Gandhi Government General 
Hospital. The study was carried out with a view to compare the efficacy of 
GBHC, Permethrin and Ivermectin as modalities of treatment for patients with 
Scabies. 
Age of 90 patients ranged from 8 to 52 years. Mean age of the study 
population was 27.66 years and standard deviation 13.213 years. Forty seven 
patients were males (52.2%) and forty three patients were females (47.8%).  
Amidst the study group, 18 patients were under the age of 14 years. Of 
that 6 patients each were treated with GBHC, Permethrin and Ivermectin. 
GBHC and Ivermectin group comprised of 3 males and 3 females each whereas 
Permethrin group comprised of 4 male children and 2 female children. 
Out of 90 patients, 62 ( 68.9%) patients were from urban area and 28 
(31.1%) patients were from rural area. 
Among 90 patients, forty patients (44.4%) patients belonged to Class IV 
socioeconomic status (according to modified Kuppuswamy scale) and 31 (34.4 
%) patients belonged to Class V (according to modified Kuppuswamy scale).  
Scabies was most common in lower socioeconomic group in our study group 
and more common among urban area. The probable reason would have been 
overcrowding and poor sanitation. 
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Forty seven patients (52.2 %) presented with symptoms of duration 
more than 15 days whereas 37 (41.1%) patients presented between eight to 
fourteen days of symptoms and six patients (6.7%) presented within a week. 
Only primary scabies cases were included in the study.  
In our study group, among 90 patients, inmates i.e. house hold contacts, 
family members, close contacts of nearly 69 patients (76.7%) were affected 
whereas among 21 patients (23.3%), inmates were not affected. 
           In the study population, out of 90 patients, 17 patients, that is 18.8 % 
had associated secondary infections. 
Out of the 90 patients studied, 8 (8.88%) patients had associated 
dermatophyte infection and 17 (18.8%) patients had associated secondary 
infection and others had no associated skin manifestations. 
  Scabies was found in high frequency among O positive individuals- 34 
(38 %) patients in our group. Second most common blood group observed was 
B positive- 25 (27.7%) patients. 
Nearly 7 patients (7.7%) were found out to be positive for Human 
Immunodeficiency Virus (HIV) infection. Out of the seven HIV positive 
individuals, six were males and one was female. 
           The 90 patients in the study were divided into three groups of 30 
patients each and started on respective treatment regimen. In GBHC group, 
there were 16 male patients and 14 female patients. In Permethrin group, there 
were 15 male patients and 15 female patients. In Ivemectin group, there were 
16 male patients and 14 female patients. 
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          The treatment response was analysed in all the treatment groups based on 
reduction in the Severity of pruritus score and Severity of Lesions score. The 
response was then graded as good, moderate and poor.  
 Among the thirty patients treated with GBHC, three patients (10%) had 
good response to treatment, with seventeen patients (56.7%) showing moderate 
response and ten patients (33.3%) showed poor response to treatment. 
 Of the thirty patients managed with permethrin, eleven patients (36.7%) 
patients showed good response to treatment. Nineteen patients (63.3%) showed 
moderate response to treatment with permethrin. 
In patients treated with Ivermectin group, twenty six patients (86.6%) 
showed good response to treatment whereas only four patients (13.3%) showed 
moderate response to treatment.  
Ivermectin compared favourably to the other two drugs with nearly 
more than three fourths of the patients having significant symptomatic 
improvement and improvement in lesions at an earlier stage. While Permethrin 
group had better response after twice application of medicine when compared 
to GBHC group  
Age and sex seemed to have no effect on the response to treatment, with 
patients across all age groups showing same pattern of response in all the three 
treatment groups. 
On analysing the severity of pruritus and severity of lesions scores, the 
Ivermectin group patients showed the maximal reduction in Severity of Pruritus 
and severity of lesions score between baseline and second application and at 
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third week follow up. The value at second week after first application of 
medicine was significant with a drop of more than eighty six percentage (86%) 
seen in patients.  
Permethrin group patients also had a higher reduction in Severity of 
pruritus score and severity of lesions score soon after completion of second 
application of medicine. At the time of third week follow up after second 
application of medicine, patients showed more than 90% improvement in 
symptoms and disease. 
In the GBHC group, the initial response is lower than that of Ivermectin 
and Permethrin with decrease in only 20% of lesions at the time of second 
application of medicine.  While at the time of third week follow up, there was 
nearly 76.7% improvement in skin lesions. 
The end points are comparable in each response group separately. 
Ivermectin group had earlier improvement in symptoms and cutaneous signs 
with nearly 86.7% reduction in severity of pruritus score and 87.8% reduction 
in severity of lesions score soon after a week of first application.  
In permethrin group and GBHC group, the initial response was 20% 
reduction in the severity of pruritus and lesions score  at the time of second 
week follow up after first application, whereas at the time of third week follow 
up after second application of medicine, Permethrin group had 70% reduction 
in severity of pruritus and lesions score while GBHC group had only 56.7% 
improvement of severity of pruritus and lesions scores. 
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None of these patients surprisingly showed any signs of adverse effects. 
Out of the 90 patients studied, there was a relapse in 7 (7.8%) of patients. 
Out of the 7 relapsed patients, 5 belonged to Group A (GBHC) and  
2 patients belonged to Group B (Permethrin). There was no relapse in group C 
(Ivermectin).  
            In Goldust et al99study, it was shown that topical ivermectin was more 
effective than Crotamiton 10% cream when used twice over a period of four 
weeks which correlates with our study showing much better response when 
compared to other scabicidal agents in our treatment groups. 
In 1986, Taplin et al100. showed a cure rate of 91% for permethrin in 
comparison with 65% for lindane in treating scabies at 4-week post-treatment. 
In another trial, Schultz et al. reported cure rates of 91% and 86.3% with 
permethrin and lindane, respectively. These two studies correlates with our 
studies as in our study permethrin has shown cure rate of more than 90%. 
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LIMITATIONS OF STUDY 
This study was not large enough to be of reasonable precision as it has 
been carried out over a limited period of time with a limited number of 
patients. All the available modalities of treatment were not assessed. All the 
facts and figures mentioned here might considerably vary from those of large 
series covering wide range of time, but still then, as the cases of this study were 
collected from a tertiary level hospital in our country, this study has some 
credentials in reflecting the facts regarding the available treatment options and 
the most favourable modality of treatment for patients. 
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SUMMARY 
Scabies is a common cutaenous infestation affecting the population of 
any age but more common in young individuals.  It is a distressing disease 
encountered frequently in clinical practice. The current mainstay of therapy is 
the use of topical permethrin and oral ivermectin along with anti-histamines. 
However, topical ivermectin is a newer drug which can be used in scabies 
patients. 
In our study we have compared the efficacy of GBHC, Permethrin and 
Ivemectin in the treatment of Scabies. The following conclusions were reached. 
 
Age and Sex Distribution : 
Young individuals were the most commonly involved group. Children 
and young individuals in the age group of 16-25 was the susceptible age group. 
There was no significant difference gender wise. This is in accordance with 
other Indian studies regarding the epidemiology of the disease. 
 
Socioeconomic status: 
Scabies was most common among lower socioeconomic status 
(according to Modified Kuppuswamy scale)in the study group which correlates 
with other Indian studies. 
 
Place of residence: 
Scabies was most common among patients from urban area in our study 
group.  
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Prevalence of Secondary skin infection : 
Out of 90 patients in the study, 17 patients turned out to have secondary 
bacterial infections. This suggests that secondary infections are common 
among scabies patients. 
 
Prevalence of associated cutaneous diseases : 
In our study group, secondary bacterial infection was the most common 
associated cutaneous disease. Next common disease observed was 
dermatophyte infection. 
 
Prevalence of HIV infection : 
In our study group, HIV infection was found to be present in 7 out of 90 
patients. Out of it six were males and one was a female. 
 
Comparison of the treatment groups : 
In the Ivermectin group, all patients had a significant reduction in their 
Severity of Pruritus and severity of lesions score, with only four patients 
having moderate response, which was explained by the fact that both those 
patients had a severe initial presentation. This response to Ivermectin was 
found to be in concurrence with studies by Goldust et al study. There was no 
evidence of relapse. 
In the Permethrin group, again there was a significant improvement in 
response compared to the GBHC group, but they compared unfavourably with 
Ivermectin group. The initial response was slower than that of Ivermectin but 
the end point was similar especially in those responding well to treatment. 
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There was no evidence of side effect but there was relapse in 2 patients. These 
findings had concordance with studies conducted by Taplin et al and Schultz 
et al. 
In the GBHC group, there was a comparatively slower reduction in the 
Severity of pruritus score and severity of lesions with response starting only 
after the second application of medicine .No side effects was observed in this 
group too. But there was relapse in 5 patients of our study group.  
 
  
CONCLUSION 
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CONCLUSIONS 
 
The following recommendations may be suggested on the basis of the 
findings of the study : 
 
1.  Topical Ivermectin can be considered as first line of treatment modality 
for scabies  as it shows earlier and maximal response when compared to 
other two drugs-permethrin and GBHC. 
 
2. Topical permethrin gives better improvement when compared to that of 
GBHC and hence can be considered as better modality of treatment when 
compared to GBHC. 
 
3. Severity of lesion score has reduced earlier and to maximum in our study 
with topical ivermectin. 
 
4. Severity of pruritus score has reduced earlier and maximum in our study 
with the use of topical ivermectin. 
 
5. Children are a source of infection as they have presented late compared to 
the adults. Hence screening of children in schools is mandatory for early 
detection of scabies to prevent spread of infection. 
 
6. The severity and duration of symptoms are more in elderly. It is essential 
to differentiate it from senile pruritus and to treat for scabies. 
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7. HIV patients have shown poor response to treatment. They are more prone 
for secondary infection. So early recognition of disease and treatment is 
needed in them. 
 
8. Face involvement can be present in children, elderly individuals and HIV 
patients. 
 
9. Routine screening for scabies is important in persons belonging to lower 
socioeconomic status especially in those living in urban areas. 
 
10. Secondary bacterial infection is more common in children and HIV 
affected individuals. Hence early recognition and treatment is important in 
these patients. 
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ANNEXURES 
 
  
  
 
ABBREVIATIONS 
 
ELISA -  Enzyme Linked Immuno Sorbent Assay 
PCR  -  Polymerase Chain Reaction 
HIV  -    Human Immunodeficiency Virus 
GBHC -  Gamma Benzene Hexa Chloride 
GABA -  Gamma Amino Butyric Acid 
Ig E  -  Immunoglobulin E 
 
 
                                             PROFORMA 
  
Case No : 
 
PATIENT DETAILS: 
 
Name :                                                    Age :            Sex:            OP No : 
 
Address :                                                Occupation : 
 
 
Housing:                                                 No of rooms: 
 
Number of members in the house: 
 
Main Complaints: 
             
H/O present illness;  
            Duration of illness 
            Sites involved 
            Progression 
H/O worsening of itching in the night 
H/O itching in the family / inmates 
H/O contact with pet animals 
H/O insect bite 
H/O drug intake prior to onset of lesions 
H/O treatment for scabies in the past 
H/O any systemic illness 
H/O any drug allergy 
Associated dermatological disorders:   Impetigo 
                                                              Cellulitis 
                                                              Furuncle 
                                                              Pyoderma 
                                                               
 CLINICAL EXAMINATION: 
General examination :                                                                 
 
Generalised lymphadenopathhy      
                                                   
Pulse : /min      BP :        /       mm of Hg    RR :      /min      Temp : 
Pallor :         Icterus : 
CVS  :   
RS :                     
P/A :   
CNS: 
Bones and joints: 
 
DERMATOLOGICAL EXAMINATION: 
 
Site of involvement:   
 
 
 
Palms and soles: 
 
Oral and genital Mucosa: 
  
Hair and nail: 
 
INVESTIGATIONS: 
Skin scrapings/ Finger nail scraping for microscopy with 10% Potassium 
Hydroxide  
 
 TREATMENT : 
Group : 
Regimen given:  
FOLLOW UP: 
Onset of remission: 
Duration of remission: 
 
Side effects:  
                               
 
  
   
 
INFORMATION SHEET 
TITLE : “EFFICACY OF TOPICAL IVERMECTIN IN COMPARISON TO 
OTHER SCABICIDAL AGENTS” 
Name of Investigator  : Dr.R.Rajalakshmi  
Name of Participant  : 
 
Purpose of Research  : The purpose of this study is to determine the 
efficacy of Ivermectin in comparison to other scabicidal agents. 
Study Design    : Prospective Observational Study 
Study Procedures  : In this study patient’s history will be taken, 
examination and mineral oil application/ burrow ink application will be done. 
Scraping will be done from burrows for microscopic examination with 10% KOH.  
The patients are then randomly grouped into 3 groups and patients will be treated 
with topical permethrin/ topical 1%GBHC or topical 0.5% ivermectin.  
Possible Risks :No risks to the patient 
Possible benefits: 
To patient :The patient will be provided with any of the above mentioned 
treatments for scabies 
To doctor & to other people :The results of the study will help to determine the 
most effective treatment for Scabies. This will help in providing better and 
complete treatment to other patients in future. 
  
Confidentiality of the information obtained from you : 
The privacy of the patients in the research will be maintained throughout the 
study. In the event of any publication or presentation resulting from the research, 
no personally identifiable information will be shared. 
Can you decide to stop participating in the study : 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time. 
How will your decision to not participate in the study affect you : 
Your decision will not result in any loss of benefits to which you are 
otherwise entitled. 
 
 
 
 
Signature of Investigator          Signature of  Participant 
 
Date : 
Place : 
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